Craft
Zymeworks

Zymeworks

Revenue

$26.7 M

FY, 2021

Market Capitalization

$446 M

2023-01-27

Zymeworks Summary

Company summary

Overview
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. Zymeworks is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. The Company's approach combines proprietary molecular modeling and simulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization.
Type
Public
Status
Active
Founded
2003
HQ
Vancouver, CA | view all locations
Website
https://www.zymeworks.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Ali Tehrani

    Ali Tehrani, President & Chief Executive Officer

  • Neil Klompas

    Neil Klompas, Executive Vice President, Business Operations and Chief Financial Officer

  • Surjit Dixit

    Surjit Dixit, Vice President, Technology

  • John Babcook, SVP, Discovery Research

    LocationsView all

    2 locations detected

    • Vancouver, BC HQ

      Canada

      1385 W 8th Ave #540

    • Seattle, WA

      United States

      1215 4th Ave #2100

    Zymeworks Financials

    Summary financials

    Revenue (Q3, 2022)
    $2.6M
    Gross profit (Q3, 2022)
    $2.2M
    Net income (Q3, 2022)
    ($47.8M)
    Cash (Q3, 2022)
    $96.1M
    EBIT (Q3, 2022)
    ($50.8M)
    Enterprise value
    $379.8M

    Footer menu